Oxford, UK [Marlborough, MA]; 17 September 2012 – Oxford Immunotec has been awarded a place
on the prestigious Sunday Times Tech Track 100 league table. Ranking Britain's 100 private
technology companies with the fastest-growing sales over the last three years, Tech Track 100 is
compiled by Fast Track, the Oxford company that researches Britain’s top-performing private
Commenting on the company’s inclusion in the top 100 list, Dr Peter Wrighton-Smith, Oxford
Immunotec’s Chief Executive Officer, said, “We are delighted to have the success of the company
recognised. Oxford Immunotec’s revenues have been growing at 60% per year over the last few
years, driven by the sales of our diagnostic for Tuberculosis to an every-increasing list of countries.
Exports now form almost 90% of our revenues, and with a global market for our test exceeding $1bn,
we expect to continue to grow strongly in the years ahead.” He added; “To be one of only three life
sciences companies in the list is a particular honour, and we are proud to be building a successful
company on the foundation of making a significant difference to the global fight against Tuberculosis
which remains a major public health threat worldwide”.
The Sunday Times Tech Track 100 league table was published in the Sunday Times yesterday.
About Oxford Immunotec
Oxford Immunotec Ltd., a global immunology-focused diagnostic company, is headquartered near
Oxford, UK; its US operations are based in Marlborough, MA. The company is developing novel new
tests in the fields of infectious and immunological disease based primarily on its patented T-SPOT® technology, the first FDA-approved method for directly quantifying antigen-specific T cells.
T-SPOT technology is a simple and extremely accurate method of studying a person’s cellular immune
response and, as such, provides a unique methodology to diagnose and monitor diseases driven by a
T cell response.
Oxford Immunotec’s primary product, the T-SPOT.TB test, is one of two Interferon-gamma release
assays (IGRAs) which detect latent TB infection and are replacing the 90-year old tuberculin skin test
currently used for this purpose. The World Health Organisation estimated in 2006 that 50 million latent
TB screening tests were performed each year, representing a greater than $1bn per annum market
opportunity for TB testing globally. IGRAs are now endorsed in clinical guidelines in over 20 countries
and the T-SPOT.TB test has now received regulatory approval in over 40 countries worldwide,
including the US, Europe and China. In the US, the T-SPOT.TB test has its own CPT®
code (86481) with recently increased CMS reimbursement of approximately $106/test. The T-SPOT.TB test is also
covered in various other clinical lab fee schedules around the world.
As well as developing & selling tests in kit form, Oxford Immunotec also runs a testing laboratory
business in both the US and the UK (Oxford Diagnostic Laboratories) designed to provide unparalleled
levels of expertise, service, turnaround time and simplicity for physicians wanting to access
immunological tests such as the T-SPOT.TB test.
T-SPOT and the Oxford Immunotec logo are registered trademarks of Oxford Immunotec Ltd.
CPT is a registered trademark of the American Medical Association